Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Retatrutide (LY3437943) is a novel incretin mimetic also created by Eli Lilly and studied for its potential in weight loss [10, 11]
Total loss by week 24 typically ranges from 12-16%
This is often the ideal time to: Learn portion control Prepare healthier meals Improve sleep habits Increase daily movement Reduce emotional eating These habits create a stronger foundation for long-term success
CBC (complete blood count): A quick health snapshot
Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record
Meguid MM, Yang ZJ, Laviano A (1997)
US$ 29.44
US$ 29.44
US$ 29.72
US$ 25.60
US$ 24.77
US$ 21.73
US$ 24.02
